DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in early brain tumor trial
Disease control TerminatedThis early study tests whether adding the drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive the combination. The…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Petrov, Andrey • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Engineered t cells take on deadly childhood brain cancer
Disease control OngoingThis early-stage trial tests a new treatment for people with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the tumor. The main goals are …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 19, 2026 11:46 UTC